BRIAN CARY: Open Payments
NPI 1376733790 · SANTA MONICA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$497 in 18 payments from 9 companies in 2025. Trend: 2023 $241 · 2024 $369 · 2025 $497
Food & beverage: $398Education: $99
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $217 |
| Gilead Sciences, Inc. | 2 | $49 |
| Merck Sharp & Dohme LLC | 2 | $49 |
| Celgene Corporation | 2 | $47 |
| Caris MPI, Inc. | 1 | $41 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| ARRAY BIOPHARMA INC | 1 | $28 |
| Stemline Therapeutics Inc. | 1 | $20 |
| Eisai Inc. | 1 | $15 |
Products named: ERLEADA, Trodelvy, KEYTRUDA, REBLOZYL, MI CANCER SEEK, RYBREVANT, LORBRENA, TALVEY.
Industry payments across CA — which companies pay providers there.
